Skip to main content
. 2018;19(1):131–139. doi: 10.22034/APJCP.2018.19.1.131

Figure 1.

Figure 1

Inhibitory Effect of Eupatorin, Salvigenin and Doxorubicin on Cell Viability in HT-29, SW948 and HFFF-2 Cell Lines. Viability of HT-29 and SW948 cells 24 h after exposure to increasing doses of A) eupatorin (25, 50, 100, 150 and 200 µM) and salvigenin (25, 50, 100, 150 and 200 µM), B) combination of eupatorin and doxorubicin, and combination of salvigenin and doxorubicin and Viability of HFFF-2 normal fibroblastic cell line and C) doxorubicin (1, 5, 10 and 20µM) 24 h after exposure to effective doses of eupatorin, salvigenin, doxorubicin and their combination as indicated. *Significantly different from control cells (*P<0.05, **P<0.01, ***P<0.001)